ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn

ARKAY Pipeline Diagram

Click to Enlarge

Why Now Is the Time to Invest, Partner & Collaborate

ARKAY is a privately-held, clinical stage comapny. Currently, there are no anti-inflammatory 'Beta cell-centric' therapies on the market. This is why the opportunity to capitalize on this cutting-edge medicine is so great.

Our lead combination product, RK-01 was efficacious and safe in the preclinical PoC studies performed using C57BL/6J DIO (Diet-induced obesity) mice with pancreatic beta-cell dysfunction and insulin resistance*.

ARKAY's product concept has been validated by human PoC for using combinations that contain Valsartan or Celecoxib for treating Type 2 diabetes. 

ARKAY Therapeutics has established fully protected intellectual space for advancing anti-inflammatory 'Beta-cell-centric' therapies. U.S. patent US 9,839,644 B2 "Formulations and Methods for Treatment of Metabolic Syndrome” was issued on December 12, 2017. It describes in detail over 60 formulations and methods for treating Type 2 diabetes, prediabetes, and metabolic disease-related disorders. A continuation patent application (Publication Number: US-2018-0042945-A1) has been filed to protect several additional patient-centric formulations and methods. ARKAY's IND application for evaluating the superiority of RK-01 over Metformin in obese type 2 diabetes patients with inadequate glycemic control was approved by the FDA in May 2018 ( Identifier: NCT03686657).

Gain a more in-depth view of our organization and the kinds of medication we’re creating by clicking here.

*ARKAY has been operating as a virtual company by collaborating with leading CROs

Type 2 Diabetes by the Numbers

Type 2 diabetes is a pandemic and the patient population is expected to double to over 600 million worldwide and over 40 million in the United States by 2040 (IDF, Facts & Figures). The prevalence of Prediabetes is three times that of Type 2 diabetes.  In 2012, 86 million Americans age 20 or older had prediabetes (American Diabetes Association). The global Type 2 Diabetes market will grow from $20.4 billion in 2012 to $58.7 billion in 2025 (FiercePharma). The global market for Metabolic Syndrome is estimated to be $72.4 billion by 2018 (Biovision). 

Diabetes Statistics
Click to Enlarge

Diabetes-Related Complications
Click to Enlarge

Understand Our Company

As a savvy investor, we understand that you’re not going to take a risk without knowing every past, present, and future aspect of our biopharmaceutical company. That’s why we invite you to get to know us and gain a sense of our potential.

Upon request, we provide the Executive Summary and the Business Plan that will cover all the information you need to make a smart, well-informed investment decision. Take a moment to read about our founder, president, and CEO, Dr. Ravi Kumar by clicking here.

ARKAY has developed a low-to-moderate risk business plan to develop and commercialize an innovative product that differentiates clinically and mechanistically for a pandemic with an enormous market potential in 4 to 5 years with a potential exit strategy in 2 to 3 years.